The Analytic for Hemodynamic Instability (AHI) from Weil Institute partner Fifth Eye, Inc. provides clinically significant lead time in predicting onset of instability before vital signs.
Read More
Fifth Eye's AHI System is the only FDA-cleared medical device software of its kind, detecting hemodynamic instability that can signal patient decompensation ahead of vital signs.
Read More
The Analytic for Hemodynamic Instability (AHI) detected the various gold standard measures of hemodynamic deterioration with high sensitivity and specificity, paving the way for further study into AHI’s potential as a surrogate measure of clinical status in settings where continuous monitoring of vital signs would not be possible.
Read More
Michigan Medicine spinoff company receives the funding to commercialize the technology as its first product.
Read More
Fifth Eye Inc. has raised $11.5 million in Series A funding led by Arboretum Ventures and Cultivation Capital. Other participants in the round included MINTS, the direct investing arm of the University of Michigan’s endowment, along with additional capital from previous investors Invest Michigan and 35 private angel investors.
Fifth Eye Press Release: https://fiftheye.com/wp-content/uploads/2019/03/fifth-eye-press-release-final.pdf
Read More
Fifth Eye Inc. raises total venture backing of $11.5M to secure FDA clearance for their first product, Analytic for Hemodynamic Instability!
Fifth Eye Press Release: https://fiftheye.com/wp-content/uploads/2019/03/fifth-eye-press-release-final.pdf
Read More
Fifth Eye Inc. raises $11.5M Series A investment to secure FDA clearance for their first product, Analytic for Hemodynamic Instability!
Fifth Eye Press Release: https://fiftheye.com/wp-content/uploads/2019/03/fifth-eye-press-release-final.pdf
Read More